News and Announcements

Choose a category:

Jul 29

Chemomab Announces CM-101 Phase 2 SPRING Trial Results

Three Recent Announcements from: Pliant, NGM, and Chemomab PSC Partners is encouraged by the initial positive data from the CM-101 Phase...

Jul 21

Positive Update on Pliant’s INTEGRIS-PSC Phase 2a Trial

On July 15, 2024, Pliant Therapeutics announced positive results from their Phase 2a INTEGRIS-PSC trial for bexotegrast in treatment of...

Jun 21

Expanded Inclusion Criteria for Mirum’s VISTAS PSC Study for Pruritus Treatment

The following is a message from Mirum Pharmaceuticals regarding their VISTAS study for volixibat, a possible new treatment for...

Sep 29, 2023

Preliminary Results from INTEGRIS-PSC Phase 2a Clinical Trial

Exciting news about the Pliant Therapeutics PSC clinical trial preliminary results from their global INTEGRIS-PSC Phase 2a trial for...

Jun 23, 2023

PRIMIS (Phase 3 Study of Cilofexor) News from EASL Congress 2023

News from the EASLCongress 2023 meeting in Vienna From the "late-breaking" abstract session on June 24, 2023, results of the pre-planned...

Sep 27, 2022

PRIMIS (Phase 3 Study of Cilofexor) News

Statement From Gilead Sciences on September 27, 2022 Early Termination of Gilead-Sponsored Study GS-US-428-4194: A Phase 3, Randomized,...

Mar 1, 2021

Proof of Concept Phase 2 Trial of IMU-838 with Early Positive Results

A proof-of-concept Phase 2 trial conducted by Mayo Clinic and sponsored by Immunic has shown very early positive results. We hope that...

Jan 28, 2021

Clinical Trials Updated: PLN 74809 and Volixibat

The clinical trials resources page has been updated on 1/27/21 to reflect two clinical trials currently recruiting. PLN 74809: Phase 2a...

Sep 22, 2020

Nutrition Study Recruiting Now (US residents)

Check out this video invitation from PSC nutrition study Principal Investigator Dr. Josh Korzenik to participate in a diet and nutrition...

ABOUT US